Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01504490 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of CS-7017 and Bexarotene
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01504490 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 9 participants.
The verdict
NCT01504490, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is for patients with advanced solid tumors. The purpose of this study is to test the safety and effectiveness of a new combination of drugs, CS-7017 and Bexarotene in patients with advanced cancer. CS-7017 and Bexarotene both have many effects on cancer cells, including stopping cancer cells from growing and dividing, and causing the cancer cells to die. CS-7017 and Bexarotene work on cancer cells in a similar manner and both drugs together may have an even greater effect against cancer cells, hopefully, increasing the killing of cancer cells. CS-7017 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration (FDA) for use in any type of cancer. Bexarotene is an anti-cancer agent that has been approved by the FDA for patients with a specific type of cancer, cutaneous T-cell lymphoma. This study will help find out what effects the combination of drugs, CS-7017 and Bexarotene, has on cancer. This research is being done because it is not known if CS-7017 is safe to be given with Bexarotene.
Interventions
- DRUG CS-7017 and Bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01504490
The ClinicalTrials.gov registry entry for NCT01504490 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CS-7017 and Bexarotene is the first listed.
NCT01504490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01504490 about?
NCT01504490 is a clinical study titled "Phase I Study of CS-7017 and Bexarotene". This study is for patients with advanced solid tumors. The purpose of this study is to test the safety and effectiveness of a new combination of drugs, CS-7017 and Bexarotene in patients with advanced cancer. CS-7017 and Bexarotene both have many effects on cancer cells, including stopping cancer ce...
What is the current status of trial NCT01504490?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2011-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01504490?
The interventions under investigation include: CS-7017 and Bexarotene (DRUG).
Who is sponsoring clinical trial NCT01504490?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.